A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient

Maguire M, Franz T, Hains DS. A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. 
Pediatr Transplantation 2011. © 2011 John Wiley & Sons A/S.

[1]  G. Nikiforidis,et al.  Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients , 2010, Therapeutics and clinical risk management.

[2]  J. Teuteberg,et al.  Elevated tacrolimus levels associated with intravenous azithromycin and ceftriaxone: a case report. , 2010, Transplantation proceedings.

[3]  S. Uemoto,et al.  Impact of Intestinal CYP2C19 Genotypes on the Interaction between Tacrolimus and Omeprazole, but Not Lansoprazole, in Adult Living-Donor Liver Transplant Patients , 2009, Drug Metabolism and Disposition.

[4]  S. Shi,et al.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics , 2008, European Journal of Clinical Pharmacology.

[5]  M. Loriot,et al.  Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. , 2006, Transplantation.

[6]  R. Yamazaki,et al.  Tacrolimus–azithromycin interaction in a recipient of allogeneic bone marrow transplantation , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[7]  T. Habuchi,et al.  Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients , 2004, Transplantation.

[8]  K. Salmela,et al.  Severe gastrointestinal complications after 1,515 adult kidney transplantations , 2004, Transplant international : official journal of the European Society for Organ Transplantation.

[9]  N. Ohkohchi,et al.  Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations , 2004, The Journal of pharmacy and pharmacology.

[10]  Marie M. Ahlström,et al.  Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[11]  W. Weimar,et al.  Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus , 2003, Clinical pharmacology and therapeutics.

[12]  T. Ishizaki,et al.  Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole , 1999, Alimentary pharmacology & therapeutics.

[13]  R. Rapp.  Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Azithromycin: Enhanced Tissue Activity and Minimal Drug Interactions , 1998, The Annals of pharmacotherapy.

[14]  P M Shaw,et al.  Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. , 1997, The Journal of pharmacology and experimental therapeutics.

[15]  I. Roots,et al.  Nonlinear kinetics after high‐dose omeprazole caused by saturation of genetically variable CYP2C19 , 1996, Hepatology.

[16]  J. Miners,et al.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. , 1993, British journal of clinical pharmacology.

[17]  D. Amacher,et al.  Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450 , 1991, Antimicrobial Agents and Chemotherapy.

[18]  U. Klotz.  Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs) , 2008, European Journal of Clinical Pharmacology.

[19]  T. Hashimoto,et al.  Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes. , 2004, Biological & pharmaceutical bulletin.

[20]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.

[21]  U. Christians,et al.  Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus , 2002, Clinical pharmacokinetics.